Esophageal adenocarcinoma

From Libre Pathology
Revision as of 16:23, 30 January 2024 by Michael (talk | contribs) (usu CK20 -ve)
Jump to navigation Jump to search
Esophageal adenocarcinoma
Diagnosis in short

Esophageal adenocarcinoma. H&E stain.
LM "invading" cell clusters or glands (gland cribriforming (more than rare) or desmoplasia or submucosa invasion); nuclear atypia of malignancy (variation of size, shape, staining), +/-mitoses
LM DDx high-grade columnar dysplasia of the esophagus, squamous cell carcinoma of the esophagus,gastric adenocarcinoma
IHC CK7 +ve, CK20 -ve, p63 -ve
Site esophagus - classically distal esophagus
Associated Dx Barrett's esophagus, high-grade columnar dysplasia of the esophagus
Symptoms dysphagia
Prevalence uncommon
Prognosis often poor - as typically high stage at diagnosis
Treatment EMR (early), surgery - esophagectomy

Esophageal adenocarcinoma, also adenocarcinoma of the esophagus, is a common malignant epithelial-derived tumour of the distal esophagus, that classically arises in the context of Barrett's esophagus.

General

  • Often a prognosis poor - as diagnosed in a late stage.
  • May be difficult to distinguish from adenocarcinoma of the stomach.
    • By convention (in the CAP checklist) gastroesophageal junction carcinomas are staged as esophageal carcinomas.[1]

Symptoms:

  • Dysphagia - difficulty swallowing.

Associations:

Treatment

Esophagus versus stomach

The convention is it's esophageal if both of the following are true:[4]

  1. Epicenter of tumour is in the esophagus.
  2. Barrett's mucosa is present.

Microscopic

Features:

  • Adenocarcinoma:
    • "Invading" cell clusters or glands.
      • Cribriforming (more than rare) or desmoplasia or "deep" invasion (into submucosa).
    • Nuclear atypia of malignancy:
      • Size variation.
      • Shape variation.
      • Staining variation.
    • +/-Mitoses (common).

DDx:

Images

  • Esophageal adenocarcinoma - very low mag. (WC)

  • Esophageal adenocarcinoma - low mag. (WC)

  • Esophageal adenocarcinoma - intermed. mag. (WC)

  • Esophageal adenocarcinoma - high mag. (WC)

Grading

Graded like other adenocarcinoma:[4]

  • >95 % of tumour in glandular arrangement = well-differentiated.
  • 95-50% of tumour in glandular arrangement= moderately-differentiated.
  • <50% of tumour in glandular arrangment = poorly-differentiated.

Staging

Early esophageal adenocarcinoma has its own staging system:[5][6]

  • M1 = lamina propria.
  • M2 = superficial muscularis mucosae.
  • M3 = submucosa.
  • M4 = muscularis propria.

IHC

  • CK7 +ve.
  • CK20 -ve.[7]

To rule-out SCC:

  • p63 -ve.
  • HWMK -ve.

Others:[8]

  • p53 +ve.
  • COX-2 +ve.
  • p16 +ve - but not that useful as it's frequently positive in the precursors.[9]

Staging

  • The number of lymph nodes is important for staging, as a small number may lead to stage migration (Will Rogers phenomenon).
  • There is no established standard for esophageal cancer (as per UICC/AJCC staging - based on Li et al.[10]), several studies give different numbers (18 lymph nodes Greenstein et al.,[11] 23 lymph nodes Peyre et al.[12]).

Sign out

Biopsy

Esophagus, Biopsy:
- INVASIVE ADENOCARCINOMA, poorly differentiated.

Comment:
Pending IHC (CK7, CK20) and HER2 testing; results of these will be reported in an addendum.

Resection

GASTROESOPHAGEAL JUNCTION, RESECTION:
- INTRAMUCOSAL ADENOCARCINOMA, pT1a, pNx, SEE TUMOUR SUMMARY.
-- MUCOSAL MARGIN HAS CAUTERIZED DYSPLASTIC EPITHELIUM, SEE COMMENT.
-- DEEP MARGIN NEGATIVE FOR MALIGNANCY.

COMMENT:
The cauterized dysplastic epithelium cannot be further interpreted. 
Malignant-appearing glands are within 1 mm of the cauterized epithelium. 
Close follow-up and re-biopsy (or endoscopic re-resection if clinically 
indicated) is recommended.

This case was partially reviewed internally. There is agreement on the presence of
intramucosal adenocarcinoma and dysplastic epithelium at the mucosal margin.

See also

References

  1. ↑ URL: http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/Esophagus_11protocol.pdf. Accessed on: 6 April 2012.
  2. ↑ 2.0 2.1 Jiang X, Tseng CC, Bernstein L, Wu AH (2014). "Family history of cancer and gastroesophageal disorders and risk of esophageal and gastric adenocarcinomas: a case-control study". BMC Cancer 14: 60. doi:10.1186/1471-2407-14-60. PMC 3915076. PMID 24495377. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915076/.
  3. ↑ Sampliner, RE. (Jul 2009). "Endoscopic therapy for Barrett's esophagus.". Clin Gastroenterol Hepatol 7 (7): 716-20. doi:10.1016/j.cgh.2009.03.011. PMID 19306943.
  4. ↑ 4.0 4.1 Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 168. ISBN 978-0781765275.
  5. ↑ Pech, O.; May, A.; Rabenstein, T.; Ell, C. (Nov 2007). "Endoscopic resection of early oesophageal cancer.". Gut 56 (11): 1625-34. doi:10.1136/gut.2006.112110. PMC 2095648. PMID 17938435. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095648/.
  6. ↑ Thosani, N.; Singh, H.; Kapadia, A.; Ochi, N.; Lee, JH.; Ajani, J.; Swisher, SG.; Hofstetter, WL. et al. (Nov 2011). "Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis.". Gastrointest Endosc. doi:10.1016/j.gie.2011.09.016. PMID 22115605.
  7. ↑ Driessen A, Nafteux P, Lerut T, Van Raemdonck D, De Leyn P, Filez L, Penninckx F, Geboes K, Ectors N (January 2004). "Identical cytokeratin expression pattern CK7+/CK20- in esophageal and cardiac cancer: etiopathological and clinical implications". Mod Pathol 17 (1): 49–55. doi:10.1038/modpathol.3800011. PMID 14631371.
  8. ↑ Liu, YS.; Yu, CH.; Li, L.; Zhang, BF.; Fang, J.; Zhou, Q.; Hu, Y.; Li, YM. et al. (Aug 2007). "Expression of p53, p16 and cyclooxygenase-2 in esophageal cancer with tissue microarray.". J Dig Dis 8 (3): 133-8. doi:10.1111/j.1443-9573.2007.00299.x. PMID 17650224.
  9. ↑ Hardie, LJ.; Darnton, SJ.; Wallis, YL.; Chauhan, A.; Hainaut, P.; Wild, CP.; Casson, AG. (Jan 2005). "p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.". Cancer Lett 217 (2): 221-30. doi:10.1016/j.canlet.2004.06.025. PMID 15617840.
  10. ↑ Li, Q.; Wu, SG.; Gao, JM.; Xu, JJ.; Hu, LY.; Xu, T. (Mar 2013). "Impact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes.". J Radiat Res 54 (2): 307-14. doi:10.1093/jrr/rrs096. PMID 23124992.
  11. ↑ Greenstein, AJ.; Litle, VR.; Swanson, SJ.; Divino, CM.; Packer, S.; Wisnivesky, JP. (Mar 2008). "Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer.". Cancer 112 (6): 1239-46. doi:10.1002/cncr.23309. PMID 18224663.
  12. ↑ Peyre, CG.; Hagen, JA.; DeMeester, SR.; Altorki, NK.; Ancona, E.; Griffin, SM.; Hölscher, A.; Lerut, T. et al. (Oct 2008). "The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection.". Ann Surg 248 (4): 549-56. doi:10.1097/SLA.0b013e318188c474. PMID 18936567.
Retrieved from "https://librepathology.org/w/index.php?title=Esophageal_adenocarcinoma&oldid=52633"